I
I C Henderson
Researcher at Harvard University
Publications - 7
Citations - 555
I C Henderson is an academic researcher from Harvard University. The author has contributed to research in topics: Metastatic breast cancer & Mitoxantrone. The author has an hindex of 5, co-authored 7 publications receiving 548 citations.
Papers
More filters
Journal ArticleDOI
Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
I C Henderson,Joseph C. Allegra,Thomas M. Woodcock,S Wolff,Shelley Bryan,K Cartwright,Gary Dukart,Dermot A. Henry +7 more
TL;DR: It is concluded that mitoxantrone can be used alone or with other standard drugs to palliate the symptoms of metastatic breast cancer, especially in settings where drug toxicity is an important consideration.
Journal ArticleDOI
Dose-response in the treatment of breast cancer: a critical review.
TL;DR: There is, as yet, inadequate evidence to justify the use of very-high-dose therapy and autologous marrow transplant outside the setting of a well-designed clinical trial, and the value of high-dose Therapy, intensive dose rate, and cumulative drug dose should each be studied in randomized controlled trials.
Journal ArticleDOI
A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer.
Joseph C. Allegra,Thomas M. Woodcock,S. Woolf,I C Henderson,Shelley Bryan,A. Reisman,Gary Dukart +6 more
TL;DR: Mitoxantrone appears to be as active as doxorubicin in patients with stage IV breast cancer previously treated with chemotherapy; however, mitoxanrone causes significantly less nausea, vomiting, stomatitis and alopecia at doses which induce equal or greater myelosuppression than doxorbicin, and seems to be less cardiotoxic.
Journal ArticleDOI
Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Charles L. Shapiro,Lois Ayash,Iain J. Webb,Rebecca Gelman,J. Keating,L Williams,George D. Demetri,P Clark,Anthony D. Elias,D Duggan,Daniel F. Hayes,D Hurd,I C Henderson +12 more
TL;DR: It is feasible to administer repetitive cycles of one-quarter dose CTCb intensification with peripheral-blood progenitor-cell (PBPC) and filgrastim (granulocyte colony-stimulating factor [G-CSF]) in advanced-stage breast cancer patients.